Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) shares rose by 7.26% to $1.25 following positive preclinical data for its lead candidate, intranasal foralumab, which indicates potential cognitive benefits and reduced neuroinflammation. The company is advancing clinical trials for conditions such as Non-Active Secondary Progressive Multiple Sclerosis and Alzheimer's disease. Despite the recent stock increase, Tiziana is trading below its 20-day and 50-day simple moving averages, with a 21.70% increase over the past year, suggesting mixed momentum in the market.